Literature DB >> 21335259

Smoker characteristics and smoking-cessation milestones.

Sandra J Japuntich1, Adam M Leventhal, Megan E Piper, Daniel M Bolt, Linda J Roberts, Michael C Fiore, Timothy B Baker.   

Abstract

BACKGROUND: Contextual variables often predict long-term abstinence, but little is known about how these variables exert their effects. These variables could influence abstinence by affecting the ability to quit at all, or by altering risk of lapsing, or progressing from a lapse to relapse.
PURPOSE: To examine the effect of common predictors of smoking-cessation failure on smoking-cessation processes.
METHODS: The current study (N=1504, 58% female, 84% Caucasian; recruited from January 2005 to June 2007; data analyzed in 2009) uses the approach advocated by Shiffman et al. (2006), which measures cessation outcomes on three different cessation milestones (achieving initial abstinence, lapse risk, and the lapse-relapse transition) to examine relationships of smoker characteristics (dependence, contextual and demographic factors) with smoking-cessation process.
RESULTS: High nicotine dependence strongly predicted all milestones: not achieving initial abstinence, and a higher risk of both lapse and transitioning from lapse to complete relapse. Numerous contextual and demographic variables were associated with higher initial cessation rates and/or decreased lapse risk at 6 months post-quit (e.g., ethnicity, gender, marital status, education, smoking in the workplace, number of smokers in the social network, and number of supportive others). However, aside from nicotine dependence, only gender significantly predicted the risk of transition from lapse to relapse.
CONCLUSIONS: These findings demonstrate that (1) higher nicotine dependence predicted worse outcomes across every cessation milestone; (2) demographic and contextual variables are generally associated with initial abstinence rates and lapse risk and not the lapse-relapse transition. These results identify groups who are at risk for failure at specific stages of the smoking-cessation process, and this may have implications for treatment.
Copyright © 2011 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21335259      PMCID: PMC3058636          DOI: 10.1016/j.amepre.2010.11.016

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  61 in total

Review 1.  Environments as cues to smoke: implications for human extinction-based research and treatment.

Authors:  Cynthia A Conklin
Journal:  Exp Clin Psychopharmacol       Date:  2006-02       Impact factor: 3.157

2.  Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers.

Authors:  Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark
Journal:  J Consult Clin Psychol       Date:  2006-04

3.  Life before and after quitting smoking: an electronic diary study.

Authors:  Danielle E McCarthy; Thomas M Piasecki; Michael C Fiore; Timothy B Baker
Journal:  J Abnorm Psychol       Date:  2006-08

4.  Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects.

Authors:  Megan E Piper; E Belle Federmen; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Timothy B Baker
Journal:  J Abnorm Psychol       Date:  2008-02

5.  mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats.

Authors:  Olga A Dravolina; Elena S Zakharova; Elena V Shekunova; Edwin E Zvartau; Wojciech Danysz; Anton Y Bespalov
Journal:  Neuropharmacology       Date:  2006-09-11       Impact factor: 5.250

6.  Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial.

Authors:  Stuart G Ferguson; Saul Shiffman; Chad J Gwaltney
Journal:  J Consult Clin Psychol       Date:  2006-12

7.  Reliability of adult retrospective recall of lifetime tobacco use.

Authors:  Janet Brigham; Christina N Lessov-Schlaggar; Harold S Javitz; Mary McElroy; Ruth Krasnow; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2008-02       Impact factor: 4.244

8.  Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis.

Authors:  Mitchell Nides; Elbert D Glover; Victor I Reus; Arden G Christen; Barry J Make; Clare B Billing; Kathryn E Williams
Journal:  Am J Health Behav       Date:  2008 Nov-Dec

9.  Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence.

Authors:  Timothy B Baker; Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Su-Young Kim; Suzanne Colby; David Conti; Gary A Giovino; Dorothy Hatsukami; Andrew Hyland; Suchitra Krishnan-Sarin; Raymond Niaura; Kenneth A Perkins; Benjamin A Toll
Journal:  Nicotine Tob Res       Date:  2007-11       Impact factor: 4.244

10.  The collective dynamics of smoking in a large social network.

Authors:  Nicholas A Christakis; James H Fowler
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

View more
  64 in total

1.  Smoking-Specific Experiential Avoidance is Indirectly Associated with Trait Worry and Smoking Processes among Treatment-Seeking Smokers.

Authors:  Samantha G Farris; Michael J Zvolensky; Peter J Norton; Julianna Hogan; Angela H Smith; Alexander M Talkovsky; Lorra Garey; Norman B Schmidt
Journal:  Behav Med       Date:  2014-11-14       Impact factor: 3.104

2.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

3.  Isolating the role of psychological dysfunction in smoking cessation: relations of personality and psychopathology to attaining cessation milestones.

Authors:  Adam M Leventhal; Sandra J Japuntich; Megan E Piper; Douglas E Jorenby; Tanya R Schlam; Timothy B Baker
Journal:  Psychol Addict Behav       Date:  2012-05-28

4.  With others or alone? Adolescent individual differences in the context of smoking lapses.

Authors:  Megan E Roberts; L Cinnamon Bidwell; Suzanne M Colby; Chad J Gwaltney
Journal:  Health Psychol       Date:  2015-02-09       Impact factor: 4.267

5.  Economic demand analysis of within-session dose-reduction during nicotine self-administration.

Authors:  Gregory L Powell; Gabriella Cabrera-Brown; Mark D Namba; Janet L Neisewander; Julie A Marusich; Joshua S Beckmann; Cassandra D Gipson
Journal:  Drug Alcohol Depend       Date:  2019-06-20       Impact factor: 4.492

6.  Development and preliminary randomized controlled trial of a distress tolerance treatment for smokers with a history of early lapse.

Authors:  Richard A Brown; Kathleen M Palm Reed; Erika Litvin Bloom; Haruka Minami; David R Strong; Carl W Lejuez; Christopher W Kahler; Michael J Zvolensky; Elizabeth V Gifford; Steven C Hayes
Journal:  Nicotine Tob Res       Date:  2013-07-24       Impact factor: 4.244

7.  Anhedonia, depressed mood, and smoking cessation outcome.

Authors:  Adam M Leventhal; Megan E Piper; Sandra J Japuntich; Timothy B Baker; Jessica W Cook
Journal:  J Consult Clin Psychol       Date:  2013-11-11

8.  Factors predicting smoking in a laboratory-based smoking-choice task.

Authors:  Krysten W Bold; Haewon Yoon; Gretchen B Chapman; Danielle E McCarthy
Journal:  Exp Clin Psychopharmacol       Date:  2013-02-18       Impact factor: 3.157

9.  Severity of dependence modulates smokers' functional connectivity in the reward circuit: a preliminary study.

Authors:  Zhujing Shen; Peiyu Huang; Wei Qian; Chao Wang; Hualiang Yu; Yihong Yang; Minming Zhang
Journal:  Psychopharmacology (Berl)       Date:  2016-03-09       Impact factor: 4.530

10.  Ovarian Hormones and Transdermal Nicotine Administration Independently and Synergistically Suppress Tobacco Withdrawal Symptoms and Smoking Reinstatement in the Human Laboratory.

Authors:  Raina D Pang; Madalyn M Liautaud; Matthew G Kirkpatrick; Jimi Huh; John Monterosso; Adam M Leventhal
Journal:  Neuropsychopharmacology       Date:  2017-09-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.